Uniqure NV Valuation
| QURE Stock | USD 15.79 0.55 3.61% |
At this time, the company appears to be overvalued. Uniqure NV has a current Real Value of $13.81 per share. The regular price of the company is $15.79. Our model measures the value of Uniqure NV from inspecting the company fundamentals such as Return On Equity of -1.48, current valuation of 446.74 M, and Shares Owned By Insiders of 8.47 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Uniqure NV's price fluctuation is unstable at this time. Calculation of the real value of Uniqure NV is based on 3 months time horizon. Increasing Uniqure NV's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Uniqure stock is determined by what a typical buyer is willing to pay for full or partial control of Uniqure NV. Since Uniqure NV is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Uniqure Stock. However, Uniqure NV's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.79 | Real 13.81 | Hype 15.79 | Naive 20.53 |
The real value of Uniqure Stock, also known as its intrinsic value, is the underlying worth of Uniqure NV Company, which is reflected in its stock price. It is based on Uniqure NV's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Uniqure NV's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Uniqure NV helps investors to forecast how Uniqure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Uniqure NV more accurately as focusing exclusively on Uniqure NV's fundamentals will not take into account other important factors: Uniqure NV Total Value Analysis
Uniqure NV is at this time projected to have valuation of 446.74 M with market capitalization of 843.78 M, debt of 138.41 M, and cash on hands of 500.52 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Uniqure NV fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
446.74 M | 843.78 M | 138.41 M | 500.52 M |
Uniqure NV Investor Information
About 80.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.95. Uniqure NV had not issued any dividends in recent years. The entity had 1:5 split on the 31st of January 2014. Based on the key indicators related to Uniqure NV's liquidity, profitability, solvency, and operating efficiency, Uniqure NV is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Uniqure NV Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Uniqure NV has an asset utilization ratio of 1.9 percent. This indicates that the Company is making $0.019 for each dollar of assets. An increasing asset utilization means that Uniqure NV is more efficient with each dollar of assets it utilizes for everyday operations.Uniqure NV Ownership Allocation
Uniqure NV shows a total of 53.44 Million outstanding shares. The majority of Uniqure NV outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Uniqure NV to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Uniqure NV. Please pay attention to any change in the institutional holdings of Uniqure NV as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Uniqure NV Profitability Analysis
The company reported the previous year's revenue of 15.84 M. Net Loss for the year was (308.48 M) with loss before overhead, payroll, taxes, and interest of (154.08 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Uniqure NV's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Uniqure NV and how it compares across the competition.
About Uniqure NV Valuation
The stock valuation mechanism determines Uniqure NV's current worth on a weekly basis. Our valuation model uses a comparative analysis of Uniqure NV. We calculate exposure to Uniqure NV's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Uniqure NV's related companies.uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. The company also engages in developing AMT-130, a gene therapy that is in Phase III clinical study for the treatment of Huntingtons disease AMT-060, which is in Phase III clinical trial for the treatment of hemophilia B AMT-210, a product candidate for the treatment of Parkinsons disease AMT-260 for temporal lobe epilepsy AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimers disease and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Uniqure NV is traded on NASDAQ Exchange in the United States.
Uniqure NV Growth Indicators
Investing in growth stocks can be very risky. If the company such as Uniqure NV does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 47.7 M | |
| Quarterly Earnings Growth Y O Y | -0.182 | |
| Forward Price Earnings | 27.933 |
Complementary Tools for Uniqure Stock analysis
When running Uniqure NV's price analysis, check to measure Uniqure NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Uniqure NV is operating at the current time. Most of Uniqure NV's value examination focuses on studying past and present price action to predict the probability of Uniqure NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Uniqure NV's price. Additionally, you may evaluate how the addition of Uniqure NV to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |